SK390692A3 - Quinuclidine derivatives, preparation method thereof and use - Google Patents

Quinuclidine derivatives, preparation method thereof and use Download PDF

Info

Publication number
SK390692A3
SK390692A3 SK3906-92A SK390692A SK390692A3 SK 390692 A3 SK390692 A3 SK 390692A3 SK 390692 A SK390692 A SK 390692A SK 390692 A3 SK390692 A3 SK 390692A3
Authority
SK
Slovakia
Prior art keywords
compound
formula
disorders
pharmaceutically acceptable
group
Prior art date
Application number
SK3906-92A
Other languages
English (en)
Slovak (sk)
Other versions
SK278788B6 (sk
Inventor
Fumitaka Ito
Hiroshi Kondo
Kaoru Shimada
Masami Nakane
John Adams Lowe Iii
Terry J Rosen
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24845673&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK390692(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of SK278788B6 publication Critical patent/SK278788B6/sk
Publication of SK390692A3 publication Critical patent/SK390692A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SK3906-92A 1991-05-31 1992-04-28 Quinuclidine derivatives, preparation method thereof and use SK390692A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70840491A 1991-05-31 1991-05-31
PCT/US1992/003317 WO1992021677A1 (en) 1991-05-31 1992-04-28 bibNUCLIDINE DERIVATIVES

Publications (2)

Publication Number Publication Date
SK278788B6 SK278788B6 (sk) 1998-02-04
SK390692A3 true SK390692A3 (en) 1998-02-04

Family

ID=24845673

Family Applications (1)

Application Number Title Priority Date Filing Date
SK3906-92A SK390692A3 (en) 1991-05-31 1992-04-28 Quinuclidine derivatives, preparation method thereof and use

Country Status (41)

Country Link
US (3) US5807867A (de)
EP (1) EP0587723B1 (de)
JP (2) JPH0733386B2 (de)
KR (1) KR100214905B1 (de)
CN (1) CN1048492C (de)
AP (1) AP299A (de)
AT (1) ATE135006T1 (de)
AU (1) AU657552B2 (de)
BG (1) BG61694B1 (de)
BR (1) BR9206073A (de)
CA (1) CA2102179C (de)
CZ (1) CZ281403B6 (de)
DE (4) DE9290063U1 (de)
DK (1) DK0587723T3 (de)
EG (1) EG19944A (de)
ES (1) ES2084361T3 (de)
FI (1) FI114475B (de)
GR (1) GR3019687T3 (de)
GT (1) GT199200028A (de)
HU (1) HU217548B (de)
IE (1) IE72473B1 (de)
IL (1) IL102008A (de)
IS (1) IS1611B (de)
LU (1) LU91293I2 (de)
MA (1) MA22539A1 (de)
MX (1) MX9202554A (de)
NL (1) NL300250I2 (de)
NO (2) NO302701B1 (de)
NZ (2) NZ242956A (de)
OA (1) OA09867A (de)
PL (1) PL171379B1 (de)
PT (1) PT100546B (de)
RO (1) RO110499B1 (de)
RU (1) RU2103269C1 (de)
SK (1) SK390692A3 (de)
TW (1) TW204349B (de)
UA (1) UA27776C2 (de)
UY (1) UY23422A1 (de)
WO (1) WO1992021677A1 (de)
YU (1) YU48995B (de)
ZA (1) ZA923942B (de)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807867A (en) * 1991-05-31 1998-09-15 Pfizer Inc. Quinuclidine derivatives
HU221634B1 (hu) * 1991-06-20 2002-12-28 Pfizer Inc. Nitrogéntartalmú heterociklusos vegyületek fluor-alkoxi-benzilamino-származékai, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények
US5721255A (en) * 1992-08-19 1998-02-24 Pfizer Inc. Substituted benzylamino nitrogen containing non-aromatic heterocycles
US5886009A (en) * 1992-11-12 1999-03-23 Pfizer Inc. Quinuclidine derivative as a substance P antagonist
US5344830A (en) * 1992-12-10 1994-09-06 Merck & Co., Inc. N,N-diacylpiperazine tachykinin antagonists
IL109646A0 (en) * 1993-05-19 1994-08-26 Pfizer Heteroatom substituted alkyl benzylamino-quinuclidines
JP2822274B2 (ja) * 1993-05-19 1998-11-11 ファイザー製薬株式会社 Ｐ物質拮抗剤としてのヘテロ原子置換アルキルベンジルアミノキヌクリジン類
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
EP0653208A3 (de) * 1993-11-17 1995-10-11 Pfizer Substanz P Antagonisten zur Behandlung oder Verhütung des sonnenbrandes.
EP0659409A3 (de) * 1993-11-23 1995-08-09 Pfizer Substanz P Antagonisten zur Hemmung der Angiogenese.
EP0655246A1 (de) * 1993-11-30 1995-05-31 Pfizer Inc. Substanz P Antagonisten zur Behandlung von durch Helicobacter Pylori oder andere spirale Urease-positive Gram-negative Bakterien verursachten Krankheiten
IL116249A (en) * 1994-12-12 2003-07-06 Pfizer Nk-1 receptor antagonists for the treatment of neuronal damage and stroke
PE8798A1 (es) * 1995-07-17 1998-03-02 Pfizer Procedimiento de separacion de los enantiomeros del 1-azabiciclo[2.2.2] octan-3-amina, 2-(difenilmetil) -n- [[2-metoxi-5-(1-metiletil) fenil] metil]
TW458774B (en) 1995-10-20 2001-10-11 Pfizer Antiemetic pharmaceutical compositions
IL123740A0 (en) * 1997-03-28 1998-10-30 Pfizer NK-1 receptor antagonists for the treatment of delayed emesis
NZ329807A (en) * 1997-04-23 2000-07-28 Pfizer NK-1 receptor antagonists and P receptor antagonists 2-Diarylmethyl-3-amino-1-azabicyclo[2.2.2]octane derivatives and amino substituted N-containing rings as agents for treating irritable bowel syndrome
KR20010041991A (ko) * 1998-03-19 2001-05-25 다케다 야쿠힌 고교 가부시키가이샤 복소환식 화합물, 그의 제조법 및 타키키닌 수용체길항약으로서의 용도
US6387925B1 (en) * 1999-06-01 2002-05-14 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo (2.2.2) oct-3-yl amine citrate and their pharmaceutical compositions
US6255320B1 (en) * 1999-06-01 2001-07-03 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions
US6262067B1 (en) * 1999-06-22 2001-07-17 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo 2,2,2 OCT-3-yl amine dihydrochloride and their pharmaceutical compositions
JP2001172178A (ja) * 1999-10-25 2001-06-26 Pfizer Prod Inc 偏頭痛治療用のｎｋ−１レセプターアンタゴニスト及びエレトリプタン
RU2309953C2 (ru) 1999-11-03 2007-11-10 Эймр Текнолоджи, Инк. Арил- и гетероарилзамещенные тетрагидроизохинолины, фармацевтическая композиция и способ лечения на их основе
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
IL142810A0 (en) * 2000-05-03 2002-03-10 Pfizer Prod Inc Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
US7084152B2 (en) 2000-07-11 2006-08-01 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines therapeutic use thereof
US20020049211A1 (en) * 2000-09-06 2002-04-25 Sobolov-Jaynes Susan Beth Combination treatment for depression and anxiety
EP1192952A3 (de) * 2000-09-28 2003-03-26 Pfizer Products Inc. Ein NK-3 rezeptorantagonisten und ein ZNS-penetrierende NK-1 rezeptorantagonisten enthaltende Zusammensetzung zur Behandlung von Depression und Angst
CN1529600A (zh) * 2001-07-20 2004-09-15 �Ʒ� Nk-1受体拮抗剂在改变狗、猫和马的不需要行为中的用途
US6686507B2 (en) 2002-03-06 2004-02-03 Pfizer Inc Purification of 2-methoxy-5-trifluoromethoxybenzaldehyde
US6861526B2 (en) * 2002-10-16 2005-03-01 Pfizer Inc. Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine
WO2005045395A2 (en) * 2003-10-27 2005-05-19 Meyer Donald W Method of detecting bovine spongiform encephalopathy
WO2005051919A1 (en) * 2003-11-26 2005-06-09 Pfizer Products Inc. Aminopyrazole derivatives as gsk-3 inhibitors
BRPI0507325A (pt) 2004-01-30 2007-07-03 Pfizer Prod Inc antagonistas dos receptores nk-1 para melhorar a recuperação da anestesia
PT1713504T (pt) * 2004-01-30 2017-08-29 Zoetis Services Llc Conservantes antimicrobianos para obter uma formulação multidose utilizando beta-ciclodextrinas para formas galénicas líquidas
WO2005075473A1 (en) * 2004-02-02 2005-08-18 Pfizer Products Inc. Process for preparation of 1-(2s,3s)-2-benzhydr yl-n-(5-tert-butyl-2-methoxybenzyl)quinuclidin-3-amine
GEP20094640B (en) 2004-07-15 2009-03-10 Bristol Myers Squibb Co Aryl-and heteroaryl-substituted tetrahydro isoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US8362075B2 (en) 2005-05-17 2013-01-29 Merck Sharp & Dohme Corp. Cyclohexyl sulphones for treatment of cancer
EP1904069B1 (de) 2005-07-15 2018-06-13 Albany Molecular Research, Inc. Aryl- und heteroarylsubstituierte tetrahydrobenzazepine und verwendung damit zur wiederaufnahmeblockierung von norepinephrin, dopamin und serotonin
WO2007041052A2 (en) 2005-09-29 2007-04-12 Merck & Co., Inc. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
EP2698157B1 (de) 2006-09-22 2015-05-20 Merck Sharp & Dohme Corp. Verfahren zur Behandlung von Fettsäure-Synthese-Hemmern
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
CN101190330A (zh) 2006-11-30 2008-06-04 深圳市鼎兴生物医药技术开发有限公司 胆碱酯酶在拮抗速激肽药物中的应用
DK2805945T3 (da) 2007-01-10 2019-07-15 Msd Italia Srl Amid-substituerede indazoler som poly(adp-ribose)polymerase- (parp) hæmmere
CA2676357A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1
AU2008233662B2 (en) 2007-04-02 2012-08-23 Msd K.K. Indoledione derivative
EP2170076B1 (de) 2007-06-27 2016-05-18 Merck Sharp & Dohme Corp. 4-carboxybenzylamino-derivate als histondeacetylase-hemmer
WO2009111354A2 (en) 2008-03-03 2009-09-11 Tiger Pharmatech Tyrosine kinase inhibitors
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
EP2413932A4 (de) 2009-04-01 2012-09-19 Merck Sharp & Dohme Hemmer der akt-aktivität
EP2429295B1 (de) 2009-05-12 2013-12-25 Albany Molecular Research, Inc. Aryl-, heteroaryl- und heterocyclen-substituierte tetrahydroisochinoline und ihre verwendung
MX2011011907A (es) 2009-05-12 2012-01-20 Albany Molecular Res Inc 7-([1,2,4,]triazolo[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2, 3,4-tetrahidroisoquinolina y uso de la misma.
WO2010132487A1 (en) 2009-05-12 2010-11-18 Bristol-Myers Squibb Company CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF
EP2488028B1 (de) 2009-10-14 2020-08-19 Merck Sharp & Dohme Corp. Substituierte piperidine zur erhöhung der p53-aktivität und ihre verwendung
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
EP3330377A1 (de) 2010-08-02 2018-06-06 Sirna Therapeutics, Inc. Durch rna-interferenz vermittelte hemmung der catenin (cadherin-assoziiertes protein)-beta-1 (ctnnb1)- genexpression mittels kurzer interferierender nukleinsäuren (sina)
CA2807307C (en) 2010-08-17 2021-02-09 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
EP2613782B1 (de) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazolderivate als erk-hemmer
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
US9260471B2 (en) 2010-10-29 2016-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
CN103732592A (zh) 2011-04-21 2014-04-16 默沙东公司 胰岛素样生长因子-1受体抑制剂
WO2013004766A1 (en) 2011-07-04 2013-01-10 Ferrari Giulio Nk-1 receptor antagonists for treating corneal neovascularisation
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP3919620A1 (de) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Zusammensetzungen mit kurzer interferierender nukleinsäure (sina)
CN105050598B (zh) 2012-09-28 2018-04-27 默沙东公司 作为erk抑制剂的新型化合物
EP3610890A1 (de) 2012-11-14 2020-02-19 The Johns Hopkins University Verfahren und zusammensetzungen zur behandlung von schizophrenie
HUE035662T2 (en) 2012-11-28 2018-05-28 Merck Sharp & Dohme Compositions and procedures for treating cancer
RU2690663C2 (ru) 2012-12-20 2019-06-05 Мерк Шарп И Доум Корп. Замещенные имидазопиридины в качестве ингибиторов hdm2
EP2951180B1 (de) 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. 2,6,7,8-substituierte purine als hdm2-inhibitoren
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
CA3059418A1 (en) 2017-04-10 2018-10-18 Chase Therapeutics Corporation Nk1-antagonist combination and method for treating synucleinopathies
CN106977512B (zh) * 2017-05-04 2019-01-01 海门慧聚药业有限公司 制备马罗匹坦游离碱的方法
MX2019015150A (es) 2017-06-30 2020-08-13 Chase Therapeutics Corp Composiciones antagonistas de nk-1 y métodos para su uso en el tratamiento de la depresión.
EP3706742B1 (de) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Prmt5-inhibitoren
AU2019223237A1 (en) 2018-02-26 2020-09-03 Ospedale San Raffaele S.R.L. NK-1 antagonists for use in the treatment of ocular pain
KR102102109B1 (ko) * 2018-07-10 2020-04-20 성균관대학교산학협력단 N-벤즈히드릴 퀴뉴클리딘 유도체를 포함하는 나트륨 누출 채널 억제용 조성물
US11981701B2 (en) 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP4117673A1 (de) 2020-03-11 2023-01-18 Ospedale San Raffaele S.r.l. Behandlung von stammzellenmangel

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005525A1 (en) * 1988-11-23 1990-05-31 Pfizer Inc. Quinuclidine derivatives as substance p antagonists
DK0532527T3 (da) * 1990-06-01 1995-01-02 Pfizer 3-amino-2-arylquinuclidiner, fremgangsmåde til fremstilling deraf og farmaceutiske præparater indeholdende disse
DE4026743A1 (de) * 1990-08-24 1992-02-27 Teves Gmbh Alfred Blockiergeschuetzte bremsanlage fuer kraftfahrzeuge
US5716965A (en) * 1991-05-22 1998-02-10 Pfizer Inc. Substituted 3-aminoquinuclidines
US5807867A (en) * 1991-05-31 1998-09-15 Pfizer Inc. Quinuclidine derivatives
EP0533280B2 (de) * 1991-09-20 2004-12-01 Glaxo Group Limited Neue medizinische Indikation für Tachykinin-Antagonisten
GB9218334D0 (en) * 1992-08-28 1992-10-14 Ici Plc Heterocyclic compounds
US5340826A (en) * 1993-02-04 1994-08-23 Pfizer Inc. Pharmaceutical agents for treatment of urinary incontinence
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
EP0655246A1 (de) * 1993-11-30 1995-05-31 Pfizer Inc. Substanz P Antagonisten zur Behandlung von durch Helicobacter Pylori oder andere spirale Urease-positive Gram-negative Bakterien verursachten Krankheiten
US5576317A (en) * 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
ES2147889T3 (es) * 1996-01-19 2000-10-01 Lonza Ag Metodo para preparar 3-hidroxiquinuclidinol opticamente activo.
US5990125A (en) * 1996-01-19 1999-11-23 Pfizer Inc. NK-1 receptor antagonists for the treatment of cancer

Also Published As

Publication number Publication date
JPH07285965A (ja) 1995-10-31
RO110499B1 (ro) 1996-01-30
IS3871A (is) 1992-12-02
SK278788B6 (sk) 1998-02-04
PT100546A (pt) 1993-08-31
AU657552B2 (en) 1995-03-16
KR100214905B1 (ko) 1999-08-02
WO1992021677A1 (en) 1992-12-10
DK0587723T3 (da) 1996-04-01
LU91293I2 (fr) 2007-02-06
OA09867A (en) 1994-08-15
IE921729A1 (en) 1992-12-02
CN1048492C (zh) 2000-01-19
FI935297A (fi) 1993-11-29
CA2102179C (en) 1998-10-27
CZ390692A3 (en) 1994-02-16
DE69208877T2 (de) 1996-07-25
UY23422A1 (es) 1992-11-12
HU217548B (hu) 2000-02-28
RU2103269C1 (ru) 1998-01-27
JP2645225B2 (ja) 1997-08-25
BG61694B1 (bg) 1998-03-31
DE69208877D1 (de) 1996-04-11
BR9206073A (pt) 1994-12-06
AP299A (en) 1994-01-14
BG98248A (bg) 1994-07-29
FI935297A0 (fi) 1993-11-29
NO934312D0 (no) 1993-11-29
NO934312L (no) 1993-11-29
CN1067428A (zh) 1992-12-30
ES2084361T3 (es) 1996-05-01
EG19944A (en) 1997-02-27
NO302701B1 (no) 1998-04-14
UA27776C2 (uk) 2000-10-16
EP0587723A1 (de) 1994-03-23
US6222038B1 (en) 2001-04-24
CZ281403B6 (cs) 1996-09-11
IL102008A0 (en) 1992-12-30
EP0587723B1 (de) 1996-03-06
NL300250I1 (nl) 2007-02-01
HU9303393D0 (en) 1994-03-28
AP9200384A0 (en) 1992-07-31
NL300250I2 (nl) 2007-03-01
US5939433A (en) 1999-08-17
YU56492A (sh) 1995-03-27
GR3019687T3 (en) 1996-07-31
FI114475B (fi) 2004-10-29
CA2102179A1 (en) 1992-12-01
NO2007003I2 (no) 2011-04-18
IS1611B (is) 1996-10-18
MX9202554A (es) 1992-11-01
IL102008A (en) 1995-12-08
JPH0733386B2 (ja) 1995-04-12
HUT70151A (en) 1995-09-28
TW204349B (de) 1993-04-21
ATE135006T1 (de) 1996-03-15
US5807867A (en) 1998-09-15
AU1990192A (en) 1993-01-08
NO2007003I1 (no) 2007-03-26
GT199200028A (es) 1993-11-20
JPH06504292A (ja) 1994-05-19
ZA923942B (en) 1993-11-29
NZ242956A (en) 1995-06-27
IE72473B1 (en) 1997-04-23
MA22539A1 (fr) 1992-12-31
PL171379B1 (en) 1997-04-30
DE122006000066I1 (de) 2007-03-22
YU48995B (sh) 2003-04-30
PT100546B (pt) 1999-12-31
NZ270673A (en) 1997-07-27
DE9290063U1 (de) 1994-02-24
DE122006000066I2 (de) 2007-12-06

Similar Documents

Publication Publication Date Title
SK390692A3 (en) Quinuclidine derivatives, preparation method thereof and use
JP2535134B2 (ja) 縮合三環式窒素含有複素環
US5886009A (en) Quinuclidine derivative as a substance P antagonist
RU2114848C1 (ru) Фторалкоксибензиламинные производные азотсодержащих гетероциклов, фармацевтическая композиция, способ ингибирования действия вещества р у млекопитающих
FI106457B (fi) Menetelmä terapeuttisesti aktiivisten 4-amino-substituoitujen 2-atsabisyklo[3.3.1]nonaanijohdannaisten valmistamiseksi
WO1994003445A1 (en) 3-benzylamino-2-phenyl-piperidine derivatives as substance p receptor antagonists
US6008357A (en) Resolution of 1-azabicyclo[2.2.2]octan-3-amine, 2-(diphenylmethyl)-n-[[2-methoxy-5-(1-methylethyl)phenyl]methyl]

Legal Events

Date Code Title Description
MK4A Patent expired

Expiry date: 20120428

SPCT Transfer of rights of an spc

Owner name: ZOETIS LLC, US

Free format text: FORMER OWNER: PFIZER INC,US

Spc suppl protection certif: 47 5-2006

Effective date: 20130712

SPCT Transfer of rights of an spc

Owner name: ZOETIS SERVICES LLC, US

Free format text: ZOETIS LLC, US

Spc suppl protection certif: 47 5-2006

Effective date: 20160126

SPCC Change of address or name of an owner of an spc

Owner name: ZOETIS SERVICES LLC, US

Spc suppl protection certif: 47 5-2006

Effective date: 20170314

SPCE Expiry of an spc

Free format text: PRODUCT NAME: MAROPITANT; FIRST REGISTRATION NO/DATE: EU/2/06/062/001, EU/2/06/062/002, EU/2/06/062/003, EU/2/06/062/004, EU/2/06/062/005 20060929

Spc suppl protection certif: 47 5-2006

Expiry date: 20170429